NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
TSX-V:NSCI - TSX Venture Exchange - CA63000Y1034 - Common Stock - Currency: CAD
Overall NSCI gets a fundamental rating of 4 out of 10. We evaluated NSCI against 15 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NSCI have multiple concerns. NSCI is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
NSCI had negative earnings in the past year.
In the past year NSCI had a positive cash flow from operations.
NSCI had negative earnings in each of the past 5 years.
NSCI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
NSCI's Return On Assets of -32.18% is amongst the best of the industry. NSCI outperforms 86.67% of its industry peers.
With a decent Return On Equity value of -87.12%, NSCI is doing good in the industry, outperforming 73.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.18% | ||
| ROE | -87.12% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 29.18%, NSCI is doing worse than 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of NSCI has declined.
NSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NSCI has been increased compared to 1 year ago.
NSCI has more shares outstanding than it did 5 years ago.
NSCI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.30, we must say that NSCI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NSCI (-0.30) is better than 73.33% of its industry peers.
NSCI has a debt to FCF ratio of 6.14. This is a slightly negative value and a sign of low solvency as NSCI would need 6.14 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.14, NSCI belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.50 indicates that NSCI is not too dependend on debt financing.
The Debt to Equity ratio of NSCI (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.14 | ||
| Altman-Z | -0.3 |
ROIC/WACCN/A
WACC6.09%
2.3 Liquidity
NSCI has a Current Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.86, NSCI perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
NSCI has a Quick Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.59, NSCI is in line with its industry, outperforming 46.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.55% over the past year.
Looking at the last year, NSCI shows a quite strong growth in Revenue. The Revenue has grown by 13.37% in the last year.
Measured over the past years, NSCI shows a very strong growth in Revenue. The Revenue has been growing by 40.32% on average per year.
EPS 1Y (TTM)41.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)13.37%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-5.09%
3.2 Future
The Earnings Per Share is expected to grow by 34.26% on average over the next years. This is a very strong growth
NSCI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.52% yearly.
EPS Next Y100%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.26%
Revenue Next Year3.87%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.52%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 5.82, the valuation of NSCI can be described as very cheap.
Based on the Price/Forward Earnings ratio, NSCI is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.44. NSCI is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.82 |
4.2 Price Multiples
93.33% of the companies in the same industry are more expensive than NSCI, based on the Enterprise Value to EBITDA ratio.
100.00% of the companies in the same industry are more expensive than NSCI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.34 | ||
| EV/EBITDA | 25.79 |
4.3 Compensation for Growth
NSCI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NSCI's earnings are expected to grow with 45.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.14%
EPS Next 3Y45.9%
5. Dividend
5.1 Amount
No dividends for NSCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NSCI (7/18/2025, 7:00:00 PM)
0.235
+0 (+2.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.93%
Ins Owner ChangeN/A
Market Cap26.98M
Analysts80
Price Target0.84 (257.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-98.02%
Min EPS beat(2)-98.02%
Max EPS beat(2)-98.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.47%
Min Revenue beat(2)-7.14%
Max Revenue beat(2)8.09%
Revenue beat(4)3
Avg Revenue beat(4)17.69%
Min Revenue beat(4)-7.14%
Max Revenue beat(4)53.52%
Revenue beat(8)6
Avg Revenue beat(8)17.17%
Revenue beat(12)7
Avg Revenue beat(12)3.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.16%
PT rev (3m)-21.43%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-12.17%
Revenue NQ rev (3m)-12.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.82 | ||
| P/S | 0.6 | ||
| P/FCF | 10.34 | ||
| P/OCF | 6.03 | ||
| P/B | 1.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.79 |
EPS(TTM)-0.11
EYN/A
EPS(NY)0.04
Fwd EY17.19%
FCF(TTM)0.02
FCFY9.67%
OCF(TTM)0.04
OCFY16.6%
SpS0.39
BVpS0.12
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.18% | ||
| ROE | -87.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.18% | ||
| FCFM | 5.81% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score6
Asset Turnover1.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.14 | ||
| Debt/EBITDA | 4.43 | ||
| Cap/Depr | 42.5% | ||
| Cap/Sales | 4.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 280.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -0.3 |
F-Score6
WACC6.09%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y100%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.26%
Revenue 1Y (TTM)13.37%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-5.09%
Revenue Next Year3.87%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.52%
EBIT growth 1Y81.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.78%
EBIT Next 3Y72.2%
EBIT Next 5Y52.3%
FCF growth 1Y114.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y139.78%
OCF growth 3YN/A
OCF growth 5Y33.1%